In a study investigating Expression and role of VEGF-A in the Ciliary Body in adult mice, researchers found that putting a block on the simulated the V protein decreased intraocular pressure, which unexpectedly then impaired the ciliary body.
There are currently anti-VEGF-A therapies that are being successfully used to treat wet macular degeneration, diabetic macular edema and retinopathy of prematurity. There has been no evidence to say that the manner in which these drugs are being administered interferes with the ciliary body.
A constant move towards developing methods to deliver anti-VEGF continuously and to have prescribed drugs that are more potent inhibitors of VEGF is still ongoing. There are concerns that increased aggressive VEGF inhibition in the eye would have deleterious effects on the ciliary body.
The results suggest further research, including clinical trials, so that by revealing the more negative side effects of VEGF inhibition in the eye newe and improved ways will be found to block edema and blood vessel growth in the eye that does not require continuous inhibition of intraocular VEGF.